Search

Background: Omentin-1 (intelectin-1) “a new adipokine described in 2003,” acts centrally to modulate the insulin resistance, body weight, and inflammation. However, its role in the liver pathogenesis and in the metabolic consequences of the liver disorders is not fully elucidated. Aim and objectives: the aim of the study was to assess the relation of serum omentin1 with fatty liver in obese and non-obese Subjects and methods: This was a comparative case control study was conducted at Ain Shams university hospital. Patients were divided in to two group: Group1: 40 patient 20 patient with fatty liver 10 of them obese and 10 non-obese compared with 20 not have fatty live 10obese and 10 non-obese, group 2. The duration of the study ranges from 6-12 months. Results: There was statistically significant difference between the four studied subgroups as regard Omentin1 and Apelin. There was statistically significant difference between group A and group B in obese as regard Omentin1 and Apelin. Conclusion: Omentin-1 might be considered as a protective factor in the evaluation of occurrence of NAFLD, especially in central obese patients. Thus, the measurement of these novel adipokines may contribute to the evaluation of NAFLD occurrence. [ABSTRACT FROM AUTHOR]